UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Purchases 11,270 Shares of Moderna, Inc. $MRNA

Key Points

• UBS Asset Management Americas LLC increased its stake in Moderna, Inc. (MRNA) by purchasing an additional 11,270 shares, bringing its total ownership to approximately $101.98 million.
• Moderna reported a loss of ($2.13) earnings per share for the most recent quarter, surpassing analyst expectations of ($2.99), but showed a 41.1% year-over-year revenue decline.
• Analysts currently rate Moderna stock as a "Hold", with an average target price of $41.81 despite recent downgrades by several financial institutions.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 0.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,597,236 shares of the company's stock after purchasing an additional 11,270 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 0.93% of Moderna worth $101,982,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of MRNA. Deseret Mutual Benefit Administrators increased its position in shares of Moderna by 53.3% during the first quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock worth $32,000 after purchasing an additional 392 shares in the last quarter. Parallel Advisors LLC increased its position in shares of Moderna by 11.4% during the first quarter. Parallel Advisors LLC now owns 4,403 shares of the company's stock worth $125,000 after purchasing an additional 451 shares in the last quarter. Blue Sky Capital Consultants Group Inc. increased its position in shares of Moderna by 3.8% during the first quarter. Blue Sky Capital Consultants Group Inc. now owns 15,119 shares of the company's stock worth $429,000 after purchasing an additional 556 shares in the last quarter. Nissay Asset Management Corp Japan ADV increased its position in shares of Moderna by 1.4% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 40,639 shares of the company's stock worth $1,152,000 after purchasing an additional 562 shares in the last quarter. Finally, Empirical Finance LLC increased its position in shares of Moderna by 7.3% during the first quarter. Empirical Finance LLC now owns 9,215 shares of the company's stock worth $261,000 after purchasing an additional 624 shares in the last quarter. Institutional investors own 75.33% of the company's stock.

Moderna Trading Down 7.4%

MRNA opened at $23.51 on Friday. The stock's 50-day moving average price is $28.34 and its 200 day moving average price is $28.17. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $75.37. The firm has a market cap of $9.15 billion, a price-to-earnings ratio of -3.12 and a beta of 1.93.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The firm had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. During the same quarter in the prior year, the company earned ($3.33) EPS. Moderna's revenue was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. On average, research analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on MRNA shares. Cowen started coverage on Moderna in a research report on Sunday, July 13th. They set a "hold" rating for the company. Wells Fargo & Company reiterated an "equal weight" rating on shares of Moderna in a research report on Sunday, July 13th. Barclays dropped their target price on Moderna from $40.00 to $31.00 and set an "equal weight" rating for the company in a report on Monday, August 4th. Bank of America dropped their target price on Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a report on Tuesday, July 22nd. Finally, JPMorgan Chase & Co. set a $26.00 target price on Moderna in a report on Friday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, fourteen have assigned a Hold rating and four have assigned a Sell rating to the company's stock. According to MarketBeat.com, Moderna presently has a consensus rating of "Hold" and an average target price of $41.81.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.